2.1 Patients
The randomized, double-blinded, prospective clinical trial study was registered in the Chinese registry of clinical trials at http://www.chictr.org.cn (ChiCTR-IPR-17012650,12, Sep 2017). The Research Ethics Committee of the Affiliated Hospital of North Sichuan Medical College approved the study(Approved No. 2017/049). This study adhered to the applicable CONSORT guidelines. The study was carried out from January 2018 to December 2019 in the Affiliated Hospital of North Sichuan Medical College. Informed written consent was obtained from all the participants. Inclusion criteria were patients aged 18 –65 years without previous abdominal surgery; American Society of Anesthesiologists classification (ASA) I-III; ability to express pain; and undergoing elective laparoscopic colorectal cancer surgery. Exclusion criteria were: undergoing any surgery again after the elective laparoscopic colorectal cancer surgery until discharged; a history of an allergic reaction to local anesthetics or opioids; weighing less than 45 kg (to reduce the risk of anesthetic toxicity); a history of recent opioids exposure; body mass index (BMI) ≥30 kg/m2; exposure to pain medication 24 h before surgery; inability to use patient-controlled intravenous analgesia;patients undergoing resections requiring perineal incisions.
2.2 Randomization and blinding
On the surgery day, consented patients were assigned randomly to Group TAP or Control (1:1) using a computer-generated list. The random number was 20170912 set by Qi-lin Liu. Allocation concealment was ensured by enclosing assignments in sealed, opaque, sequentially numbered envelopes opened by a nurse (Yi Han) only upon the patient's arrival in the operation room. The nurse prepared 0.5% ropivacaine or saline (40 mL) for all patients in the whole study period according to the allocation and did not participate in any other related process. The allocation was blinded for all patients, surgeons, anesthesiologists, and follow-up observers until the end of the study.
2.3 sample size
The sample size was based on the 24 h rescue tramadol requirement of patients undergoing laparoscopic colorectal cancer surgery. For sample size calculation, a clinically important reduction in 24 h tramadol consumption was considered a 20% absolute reduction with a conservative assumption. We found that 24 h tramadol requirement was 110 ±34.2 mg in the control group of 10 subjects based on initial pilot studies. With a statistical power of 0.8 and a type 1 error rate of 0.05 to detect 20% improvement as conservative, a sample size of 38 patients per group was the minimum requirement to demonstrate difference using a two-tailed Student's t-test. Considering a possible dropout rate of 20%, we aimed to include 92 patients in this study.
2.4 Anaesthesia, surgery and postoperative analgesia
All patients received standard perioperative care. Patients were routinely monitored by electrocardiogram, non-invasive arterial blood pressure, arterial oxygen saturation, and end-tidal carbon dioxide monitoring and placed in the Trendelenburg position. General anesthesia was induced and maintained by the same procedure using intravenous midazolam (0.04 mg/kg), propofol (2.0 to 3.0 mg/kg), sufentanil (0.3µg/kg) in both groups. Endotracheal intubation was performed using IV administration of rocuronium (0.6 mg/kg). Sufentanil (10µg) and rocuronium (10 mg) were administered intravenously before the incision. Anesthesia was maintained with a combined IV–inhaled anesthesia: sevoflurane (2 - 4%) with oxygen 2 L/min, rocuronium (0.1 - 0.2 mg/kg/hour) was applied to maintain muscle relaxation, and remifentanil (0.1 µg/kg/min) was used to maintain intra-operative analgesia. Sevoflurane end-tidal concentrations were titrated to maintain bispectral index value at 40 to 60 for all patients. The infusion of IV atropine and ephedrine was used to maintain blood pressure and heart rate at the preoperative baseline range (the increase and decrease width did not exceed 20% of the baseline value). All patients were intravenously administered with 0.15µg/kg sufentanil, following with the patient-controlled intravenous anesthesia (PCIA) 30 min before surgery finished. The PCIA contained 100µg sufentanil and 98 mL saline; PCIA was set as follows: background infusion of 2µg/h sufentanil, a bolus dose of 2µg sufentanil, and lockout interval of 5 min [11].
The postoperative intravenous antiemetic regimen consisted of dexamethasone (5mg) administered at induction and ondansetron (4mg) after surgery. After the surgery, anesthesiologists performed ultrasound-guided bilateral posterior TAP block for all patients. After patients awakened, the tube was extubated, and they were transferred to the post-anesthesia care unit (PACU) for further monitoring. If the patient complained of a numerical rating score (NRS) higher than 3, a muscular injection of rescue tramadol was offered. Rescue antiemetics were also provided to patients complaining of nausea or vomiting. Early mobilization was encouraged since the patient transferred to the ward. Patients met the discharge criteria when they could have a soft diet, fully mobilized, and had an NRS score lower than 3.
2.5 Intervention
Before the extubation, all patients received ultrasound-guided bilateral posterior TAP block by an experienced anesthesiologist at the end of the surgery. The patient was kept in a semi-lateral position and received the posterior TAP block. An ultrasound probe was placed posterior to the mid-axillary line between the costal margin and the iliac crest [12](Fig. 1). When scanning posteriorly, transversus abdominis tails off and turns into the aponeurosis. Subsequently, a blunt-ended needle was injected at the TAP between the internal oblique and transversus abdominis, posterior to the mid-axillary line and near the aponeurosis. Real-time imaging allowed the anesthesiologist to observe the needle passage through the internal oblique and enter the TAP endpoint near the aponeurosis. Correct placement of the needle was confirmed upon injecting saline solution into the muscle plane, creating a spreading of the planes. After the confirmation, 40 mL 0.5% ropivacaine was injected (20 mL per side) in Group TAP and equivalent saline in Group Control. The successful injection was defined as the appearance of a hypoechoic ellipsoid with well-defined margins in the ultrasonic imaging.
2.6 Follow-up and outcomes
Patients were evaluated from PACU until discharge from the hospital by the same investigator blind to the randomization. The primary outcome was the cumulative consumption of rescue tramadol within 24 h after surgery. Secondary endpoints include : (1) the resting and movement NRS scores assessed at 2, 4, 6, 12, 24, 48, and 72 h, postoperatively. The side effects, such as nausea, vomiting, pruritus, sedation, and respiratory depression, were also recorded. (2) Time to the first requirement of rescue tramadol muscular injection. (3) Patient satisfaction on postoperative analgesia at 24, 48, and 72 h after surgery using a 5-point scale [13] (1 = very unsatisfied, 2 = unsatisfied, 3 = fair, 4 = satisfied, and 5 = very satisfied). (4) Time for the return of intestinal function. (5) Time to the first mobilization. (6) Length of hospital stay (number of nights spent in the hospital from the date of surgery to discharge).
2.7 Statistical analysis
The collected data was analyzed using SPSS 25.0 software (Statistical Program for Social Sciences, SPSS Inc, Chicago, Illinois, USA), with a 2-tailed p-value <0.05 considered statistically significant. Continuous variables were presented as means ±standard, or medians ± interquartile range (IQR), or absolute numbers. Categorical variables were presented as percentages. The two-sample Student t-test or the Mann–Whitney U-test was used for continuous variables, and the Chi-squared test compared differences in the qualitative data.